Exciting developments are underway in the world of nanomedicine, as researchers unveil a pioneering study on self-assembled cannabigerol-based nanoparticles.
Published in Pharmaceutics on 11 May 2025, this research was carried out in collaboration with the University of Milan, the University of Padua, and Linnea, who also provided the high-purity cannabigerol (CBG) used in the study. The research explored the synthesis of self-assembling drug conjugates using CBG as a self-assembly nanoparticle inducer. Such nanoparticles, designed with precision, show promise not only for enhancing drug delivery systems but also for offering significant antiproliferative effects against cancer cells.
Though further investigation is needed to validate these findings, this study could pave the way for new therapeutic strategies in the fight against cancer, leveraging the unique properties of cannabinoids to improve drug efficacy and targeted delivery.